A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study-Reference-Cited by-同舟云学术

A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study

Published:2021-06-19 Issue:3 Volume:8 Page:1159-1176
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Cohen Stanley,Wells Alvin F.,Curtis Jeffrey R.,Dhar Rajat,Mellors Theodore,Zhang Lixia,Withers Johanna B.,Jones Alex,Ghiassian Susan D.,Wang Mengran,Connolly-Strong Erin,Rapisardo Sarah,Gatalica Zoran,Pappas Dimitrios A.,Kremer Joel M.,Saleh Alif,Akmaev Viatcheslav R.

Funder

Scipher Medicine Corporation

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s40744-021-00330-y.pdf

Reference70 articles.

1. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.

2. Aletaha D. Precision medicine and management of rheumatoid arthritis. J Autoimmun. 2020;110:102405.

3. Bluett J, Barton A. Precision medicine in rheumatoid arthritis. Rheum Dis Clin North Am. 2017;43(3):377–87.